Mining real world data for drug development insights, Woodford-backed AI firm seeks $77M London IPO
Putting the words “artificial intelligence” near drug development these days is a sure way to generate buzz. But can it support a $77 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
